Business Context and Reporting Period
This Form 8-K is a current report filed by GlycoMimetics, Inc. (not Crescent Biopharma, Inc.) on March 10, 2014. The filing addresses a corporate governance event involving the Board of Directors and compliance with NASDAQ listing rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a non-financial corporate event.
Material Changes
The primary material change reported is the unexpected death of Mr. William Gust, an independent member of the Board of Directors and the Audit Committee, on March 4, 2014. Consequently, the Company notified NASDAQ of non-compliance with Listing Rule 5605 regarding the composition of its Audit Committee.
Guidance, Outlook, and Risks
Management has determined to rely on the cure period set forth in NASDAQ Listing Rule 5605(c)(4)(B). NASDAQ acknowledged the non-compliance and granted a cure period to regain compliance by the earlier of the next annual stockholders meeting or March 4, 2015. If the next annual meeting occurs before September 1, 2014, compliance must be evidenced by September 1, 2014. The Company expects to regain compliance prior to the expiration of this period. No financial guidance or other risks were disclosed in this specific filing.
Investor Verification Checklist
- Verify the appointment of a new independent director to the Audit Committee to ensure compliance with NASDAQ rules.
- Confirm the date of the next annual stockholders meeting to determine the exact deadline for regaining compliance.
- Review subsequent filings to ensure the cure period was utilized successfully and no delisting proceedings were initiated.